Subdermal norethindrone pellets -- a method for contraception?
The mode of action of compressed pellets containing 85 per cent norethindrone (NET) and 15 per cent cholesterol was studied. Four pellets were inserted subcutaneously, in each of five healthy volunteers and left in place for 200--229 days. The NET content of the pellets varied between 23.9 mg and 25.6 mg; and the cholesterol content between 4.2 mg and 4.5 mg. Plasma levels of NET, estradiol and progesterone were determined by radioimmunoassays. Plasma levels of NET varied mostly between 1--2 ng/ml the first month after insertion. After two months plasma levels of NET ranged between 0.5 ng/ml and 1 ng/ml in all volunteers and there was a gradual decrease of the plasma NET levels throughout treatment. Pronounced day-to-day variations in plasma NET levels were recorded. The release rates of NET was calculated to be between 187 micrograms/day and 243 micrograms/day among the five volunteers. Ovulations occurred in four out of five subjects during treatment. This study indicates that the release of gestagen from four NET pellets was only initially high enough to completely inhibit ovulation and that to accomplish full contraceptive efficacy, a higher dose, i.e. more pellets, would have to be inserted.
D000328:Adult; D002784:Cholesterol; D003267:Contraception / Q000379:methods*; D004338:Drug Combinations; D004343:Drug Implants; D004958:Estradiol / Q000097:blood; D005260:Female; D005298:Fertility / Q000187:drug effects*; D006801:Humans; D008598:Menstruation / Q000187:drug effects; D009640:Norethindrone / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D010060:Ovulation / Q000187:drug effects; D014677:Pharmaceutical Vehicles; D011247:Pregnancy; D011374:Progesterone / Q000097:blood
D004338:Drug Combinations; D004343:Drug Implants; D014677:Pharmaceutical Vehicles; D011374:Progesterone; D004958:Estradiol; D002784:Cholesterol; D009640:Norethindrone